AbbVie registers Phase 3 trial of upadacitinib in pediatric non-segmental vitiligo
The study will enroll approximately 154 participants aged 6 to <12 years and is expected to start on January 28, 2027. It is to evaluate the efficacy, safety, and tolerability of upadacitinib over 48 weeks of treatment followed by 112 weeks of continued blinded therapy.
Primary source
ClinicalTrials.gov registry record, October 27, 2026
A Study to Learn How Effective, Safe, and Tolerable Upadacitinib is for Young Participants With Non-segmental Vitiligo
Read the source: A Study to Learn How Effective, Safe, and Tolerable Upadacitinib is for Young Participants With Non-segmental Vitiligo clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation